# Long-Term Integrated Safety and Efficacy of Garadacimab for Hereditary Angioedema Prophylaxis.

- **DOI:** [10.1007/s12325-026-03628-x](https://doi.org/10.1007/s12325-026-03628-x)
- **Rating:** Sound (3.0 out of 5)
- **Verdict:** Integrated garadacimab follow-up extends long-term safety evidence and documents sustained attack suppression, but uncontrolled extension data limit confirmation of durable efficacy.
- **Framework version:** v5.10
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-11-02
- **Evaluation page:** https://www.nabu.science/paper/10.1007%2Fs12325-026-03628-x

## Key claims

1. These integrated data, representing the longest garadacimab exposure reported to date, confirm the favorable long-term safety profile of garadacimab (exposure ≤ 5.5 years), and durable efficacy with sustained protection against HAE attacks (exposure ≤ 3.2 years).
   - Support: Tentative
   - Type: Primary finding
   - Basis: uncontrolled long-term extension evidence supports observation of persistence rather than confirmation of durable efficacy
   - Location: Abstract
2. The mean (95% confidence interval) monthly attack rate was 0.2 (0.1, 0.2) with garadacimab (n = 164), corresponding to a 94.9% (93.1, 96.7) reduction from run-in (3.5 [3.2, 3.9]).
   - Support: Supported
   - Type: Secondary
   - Basis: descriptive treatment-versus-run-in comparison documents a large reduction without a concurrent long-term control
   - Location: Abstract, Results, Efficacy Outcomes
3. 98.2% of patients who received garadacimab (n = 161/164) had a ≥ 50% reduction in attack rate and 84.8% (n = 139/164) had a ≥ 90% reduction
   - Support: Supported
   - Type: Secondary
   - Basis: reported responder counts support the descriptive proportions within a pooled extension and run-in comparison
   - Location: Results, Efficacy Outcomes
4. These data confirm a favorable safety profile with low rates of ISRs and no abnormal bleeding or thromboembolic events.
   - Support: Tentative
   - Type: Secondary
   - Basis: descriptive safety follow-up includes one mild unrelated bleeding event omitted by the unqualified conclusion
   - Location: Conclusion

## Strengths

- **Safety reporting connects events with exposure** Tables 2–3 report adverse events with patient denominators, exposure-adjusted rates, severity, and relatedness. Serious events and all four adverse-event-related discontinuations are described.
  - Dimension: methodological rigour
  - Location: Results, Safety Outcomes, Tables 2–3
- **Continuous tracking extends accumulated safety observation** Unique patient identifiers connect follow-up across three studies, extending maximum safety exposure to 5.5 years. This adds observation relevant to a treatment intended for lifelong prophylaxis.
  - Dimension: contribution
  - Location: Methods, Study Design; Results, Baseline Characteristics and Exposure
- **Efficacy estimates remain numerically traceable throughout** The report gives attack-rate confidence intervals and explicit responder numerators and denominators. It also explains why one placebo participant was excluded from the efficacy analysis.
  - Dimension: reporting
  - Location: Results, Baseline Characteristics and Exposure; Efficacy Outcomes

## Limitations

- **Long-term confirmation exceeds the comparative design** Later efficacy observations principally derive from open-label extension and run-in comparisons rather than a concurrent long-term control. The randomized parent phase does not establish comparative durability throughout subsequent follow-up.
  - Dimension: methodological rigour
  - Location: Methods, Study Design and Analysis; Results, Efficacy Outcomes; Conclusion
- **Durability limitations remain outside the interpretation** The Discussion addresses statistical power and sex-specific analysis but does not explain how selection, attrition, or the missing long-term comparator constrain its durability conclusion.
  - Dimension: positioning
  - Location: Discussion, durability and limitations paragraphs
- **No-bleeding conclusion omits a necessary qualifier** The Conclusion states that no abnormal bleeding occurred, although Results reports one mild, unrelated epistaxis AESI. The defensible statement is that no garadacimab-related abnormal bleeding was observed.
  - Dimension: reporting
  - Location: Results, Safety Outcomes; Conclusion

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Noted
  - These data confirm a favorable safety profile with low rates of ISRs and no abnormal bleeding or thromboembolic events: "no abnormal bleeding or thromboembolic events" (Conclusion) vs "a patient receiving garadacimab 600 mg experienced one episode of mild, unexplained epistaxis" (Results, Safety outcomes). One abnormal-bleeding AESI was reported, so the conclusion requires the treatment-related qualifier used elsewhere in the safety results. → Conclusion holds
  - Minor reporting notes (1):
    - Descriptive: "75/200/600 mg monthly or 400 mg every 2 weeks" (Abstract, Methods) vs "randomized to 75 mg, 200 mg, 400 mg, or 600 mg garadacimab Q4W" (Methods, Study design). The Abstract assigns the 400 mg arm an every-two-weeks schedule, whereas Methods describes that arm as Q4W. → Conclusion holds
- **Reporting and transparency:** Clean. Ethics approval, consent, and registration of the parent trials are declared, and the pooled analysis is identified as post hoc. Unavailable supporting materials and unstated availability disclosures do not establish suspicious conduct.
  - Ethics approval: declared · Preregistration: declared
- **Reference integrity:** Clean
  - 30 references in manuscript
  - 22 of 22 checkable references found in an index
  - 8 are books, websites or datasets — counted, but not index-checkable
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-11-02
